LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

4.21 1.94

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.03

Максимум

4.34

Ключови измерители
By Trading Economics
Приходи	-31M -14M
Продажби	-32M 41M
EPS	-0.22
Марж на печалбата	-34.333
Служители	293
EBITDA	-37M -15M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+52.16% upside

Дивиденти
By Dow Jones
Следващи печалби	19.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	65M 188M
Предишно отваряне	2.27
Предишно затваряне	4.21

Настроения в новините

By Acuity

75%

25%

319 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.05.2026 г., 22:47 ч. UTC

Горещи акции

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15.05.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15.05.2026 г., 22:00 ч. UTC

Значими двигатели на пазара

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15.05.2026 г., 18:09 ч. UTC

Значими двигатели на пазара

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15.05.2026 г., 16:02 ч. UTC

Печалби

Значими двигатели на пазара

Forward Industries Shares Fall on New Debt as Solana Value Drops

15.05.2026 г., 14:55 ч. UTC

Значими двигатели на пазара

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15.05.2026 г., 14:43 ч. UTC

Значими двигатели на пазара

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15.05.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15.05.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15.05.2026 г., 21:16 ч. UTC

Пазарно говорене

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 20:19 ч. UTC

Горещи акции

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15.05.2026 г., 19:41 ч. UTC

Придобивния, сливания и поглъщания

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15.05.2026 г., 19:35 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15.05.2026 г., 18:35 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15.05.2026 г., 17:28 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15.05.2026 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15.05.2026 г., 16:24 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Silver Plunges on Inflation Worries -- Market Talk

15.05.2026 г., 15:20 ч. UTC

Печалби

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15.05.2026 г., 14:33 ч. UTC

Пазарно говорене

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

52.16% нагоре

12-месечна прогноза

Среден 6.33 USD 52.16%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

319 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.